The rising need for – anti osteoarthritis treatments, the prevalence of lifestyle-related illnesses, and improvements in the creation of hyaluronic acid-based therapies are all projected to propel the global viscosupplementation injection market forward.
It’s being expected that by 2028, the Viscosupplementation Injection market cap will hit USD 7.58 billion at a CAGR growth of about 9.37 %.
Covid-19 Impact & Market Status
The global viscosupplementation injection market was severaly impacted since the majority of viscosupplementation product users are older folks, a group that has been advised to stay at home to avoid infection.
The widespread cancellation of elective surgical operations in hospitals lowered sales of viscosupplementation products, costing manufacturers a large amount of money. In the second quarter of 2020, for example, Anika Therapeutics' overall sales fell by 13%.
In COVID-19 constraints, surgery volumes are likely to recover quickly. For example, by the end of June 2020, surgical volumes in the United States, China, Germany, and Australia had begun to recover. As the number of osteoarthritis procedures increases, so will the need for viscosupplementation products.
Single Injection Viscosupplementation Injection Promises High Revenue Growth
The global viscosupplementation injection market is classified into single, three, and five injections on the basis of product. With a market share of nearly 47 percent in 2020, single-injection ranked arguably the dominant product category. For the last twenty years, multiple three injections have been accessible and also have gained a considerable portion of the global viscosupplementation injection market. The segment's growth is likely to be aided by an increasing number of FDA approvals for single-injection viscosupplements.
Orthopedic Clinics/ASCs Have The Largest Market Share In Viscosupplementation Injection Market
The global viscosupplementation injection market is divided into hospitals and orthopaedic clinics/ambulatory surgical centres based on end-use ASCs. Due to the increased demand for standard therapy, the orthopaedic clinics/ASCs category held the major global viscosupplementation injection market share of over 59 percent in 2020 and is predicted to grow just at quickest CAGR of 10 percent throughout the forecast timeframe. ASCs are ambulatory surgery facilities that concentrate on the same day surgical treatment, including both preventative and diagnostic procedures.
ASCs may conduct ACL surgery, hip, knee, and various joint replacement, among other procedures, on the same day. Some procedures are less difficult and do not require medical attention. On addition, orthopaedic clinics specialise in the treatment of the musculoskeletal system. This encompasses the surgical and non - surgical therapy of joint, bone, ligament, muscle, spine, and nerve issues.
APAC Region Is Dominating The Viscosupplementation Injection Market Growth.
APAC is the dominant region among all the other regions. During the projected period, an increase in incidence of rheumatoid illness is likely to drive market expansion in the area. The number of incidents of rheumatoid in India, for example, has climbed from 185,272 in 2007 to 265,365 in 2017 resulting into higher demand of viscosupplementation. As a result, by examining the amount of instances in other key Asia Pacific nations, as well as the healthcare actions in relation to them, As a result, based on the number of patients in other key Asian nations, the healthcare activities related to the treatment of rheumatoid arthritis will move the global viscosupplementation injection market forward.
because of the huge ageing population, which is more vulnerable to diseases like osteoarthritis However, due to factors such as the expanding rising geriatric population and higher investments by market participants, Europe is predicted to have the quickest CAGR throughout the forecast period.
The global viscosupplementation injection market is predicted to rise due to an increase in product releases and FDA requirements of viscosupplementation injection products.
The global viscosupplementation injection market is expected to have a market size of USD 5 billion at a CAGR of 9.37 percent between 2022 and 2029.
Viscosupplementation is a noninvasive treatment in which hyaluronic acid is infused into the knee joint to improve joint growth and smoothness. It also aids in the reduction of pain and inflammation, as well as the improvement of osteoarthritis symptoms. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan found in epithelium, tendons and ligaments, and neural tissues throughout the body. Demand for viscosupplementation products is predicted to rise as the prevalence of osteoarthritis rises. Viscosupplements on the market have been demonstrated to be the most effective therapy for knee osteoarthritis in clinical trials. Osteoarthritis is a degenerative joint condition that causes chronic pain and is the major cause of chronic disability. The ailment usually appears after 30 years of age, and after 10 years of diagnosis, it might proceed to become a handicap.
According to WHO projections, the earth's population people aged 65 and more is expected to grow from 7% in 2000 to 16% in 2050, resulting in an increase in obesity and osteoarthritis. As a result, throughout the forecast timeframe, the world dominance in the target population, together with a rising desire for alternative treatment choices for corticosteroid for joint pain management, is predicted to considerably accelerate product demand.
The growing market for viscosupplementation Injection solutions has proactively involved to focus their efforts on developing and marketing new viscosupplementation solutions. For example, in March 2018, Bioventus, a producer of orthobiologic solutions, introduced DUROLANE, a single-injection hyaluronic acid (HA) medication used only for joint lubrication and pain relief in patients with osteoarthritis of the knee . In addition, Bioventus got clearance from the Agência Nacional de Vigilância Sanitària (ANVISA) in October 2018 to commercialise DUROLANE in Brazil.
Demand for viscosupplementation injection products is increasing due to the rising incidence of osteoarthritis and other joint pain diseases, which is likely to boost the global viscosupplementation injection market over the forecast period. When a simple painkiller or medication therapy fails to provide significant comfort for people with osteoarthritis, hyaluronic acid injections are generally given. Injections of hyaluronic acid are administered in the knee to meet the body's demand for hyaluronate (naturally generated by the body) in synovial fluid for appropriate function and lubricating. In addition, the rise in the prevalence of knee and hip osteoarthritis has resulted in a rise in demand for viscosupplementation injection products. According to the National Center for Biotechnology Information (NCBI), osteoarthritis was the most frequent joint ailment in the United States in 2014, and it affected more women than men. Knee osteoarthritis (KOA) affects around 10 percent of total of men and 13 percent of women over the age of 60.
One of the primary factors projected to support the growth of this sector is the rising prevalence of osteoarthritis among elderly. Viscosupplementation is performed in hospitals as an outpatient operation, and the patient is alleviated within several hours. Viscosupplementation operations are normally conducted in a hospital on the suggestion of a medical doctor or orthopedist. Patients choose hospitals when orthopaedic clinics are lacking, which is common in underdeveloped nations. Patients are compelled to visit a hospital on a certain day in these nations, where an orthopaedic physician is generally a visiting faculty member. Furthermore, because viscosupplementation requires no additional expenditure, the majority of multispecialty hospitals across the world provide it.
The key players operating in the global viscosupplementation injection market are Hoffmann-La Roche, Fidia Farmaceutici S.p.A, F., LG Life Sciences, Lifecore Biomedical, Ferring Pharmaceuticals B.V., Smith & Nephew PLC, Zimmer Biomet, Seikagaku, Anika Therapeutics, and Sanofi among others.
These companies' main growth strategies include expansion, new product development, and cooperation in order to improve their product range and geographical presence to address the rising demand for Viscosupplementation Injection from emerging nations.
Latest Innovation in the Global Viscosupplementation Injection Market: A snapshot
- HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis, was launched in Taiwan by Seikagaku Corporation in August 2021.
Viscosupplementation Injection Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 5 billion|
|Growth Rate||CAGR of 9.37 % during 2021-2028|
|Segment Covered||Product, End Use, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Hoffmann-La Roche, Fidia Farmaceutici S.p.A, F., LG Life Sciences, Lifecore Biomedical, Ferring Pharmaceuticals B.V., Smith & Nephew PLC, Zimmer Biomet, Seikagaku, Anika Therapeutics, and Sanofi among others.|
Key Segments of the Global Viscosupplementation Injection Market
Product Overview, 2019-2029 (USD Billion )
- Single Injection
- Three Injection
- Five Injection
End Use, 2019-2029 (USD Billion )
- Orthopedic Clinics/ASCs
Regional Overview, 2019-2029 (USD Billion )
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and South Africa